Brief: U.S. FDA Approves Kygevvi® (Doxecitine And Doxribtimine), The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d)
03/11/2025 23:01
Ucb SA UCB.BR: U.S. FDA APPROVES KYGEVVI® (DOXECITINE AND DOXRIBTIMINE), THE FIRST AND ONLY TREATMENT FOR ADULTS AND CHILDREN LIVING WITH THYMIDINE KINASE 2 DEFICIENCY (TK2D) Source text: ID:nPnNGGlGa Further company coverage: UCB.BR
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside